Curium Extends Lutetium-177 Supply Partnership With NRG I PALLAS in Netherlands

Curium, a leading entity in nuclear medicine globally, has struck a new long-term deal with NRG I PALLAS to continue and expand their partnership for irradiation services in Petten, Netherlands. This agreement aims to boost the production of non-carrier added lutetium-177 (Lu-177), an essential isotope for cancer therapy. The enhanced cooperation is projected to benefit over 100,000 critically ill patients internationally over the next five years.

For over four decades, the High Flux Reactor (HFR) in Petten has been a cornerstone for the production of molybdenum-99 (Mo-99), pivotal for patient diagnostics, and more recently, for Lu-177. By leveraging the HFR's capabilities, Curium can meet the increasing demand for Lu-177 throughout the year, ensuring a stable supply of this crucial cancer treatment isotope.

Ciril Faia, CEO of SPECT Europe for Curium, expressed satisfaction with the extended partnership, emphasizing its role in meeting the rising global demand for Lu-177. According to Faia, Lu-177 is already revolutionizing treatment for neuroendocrine tumors (NETs) and prostate cancer and holds potential for treating around 20 other conditions currently under (pre)clinical trials and development.

Bertholt Leeftink, CEO of NRG I PALLAS, echoed this sentiment, highlighting the long-standing collaboration between Curium and NRG I PALLAS since 1995. The renewed partnership guarantees a continuous supply of Lu-177, supporting Curium's innovative pipeline for patient therapies.

Both Curium's Lu-177 production facility and NRG's HFR reactor are situated on the Energy & Health Campus in Petten. To support its Lu-177 product platform, Curium has established several production lines at its Petten facilities, which commenced operations in early 2024.

Curium is recognized globally for its contributions to nuclear medicine, developing, manufacturing, and distributing high-quality radiopharmaceutical products. The company provides SPECT, PET, and therapeutic radiopharmaceutical solutions to over 14 million patients annually. Curium's name honors Marie and Pierre Curie, pioneering researchers of radioactive materials, reflecting its dedication to nuclear medicine.

NRG I PALLAS is a leader in developing new nuclear technologies, with the HFR reactor producing critical medical isotopes essential for diagnosing and treating life-threatening diseases. The HFR serves over 30,000 patients daily, and its successor, the PALLAS reactor, is expected to play a key role in the global supply chain for radiopharmaceuticals.